UCB SA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.73 USD | -0.77% |
|
-0.10% | +78.28% |
| Sales 2024 * | 565.1Cr 615.57Cr 51TCr | Sales 2025 * | 643.68Cr 701.17Cr 59TCr | Capitalization | 2.73TCr 2.97TCr 2,48400Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 41Cr 44Cr 3.69TCr | Net income 2025 * | 86Cr 94Cr 7.83TCr | EV / Sales 2024 * | 5.13 x |
| Net Debt 2024 * | 166.97Cr 181.89Cr 15TCr | Net Debt 2025 * | 83Cr 91Cr 7.58TCr | EV / Sales 2025 * | 4.37 x |
| P/E ratio 2024 * |
68.7
x | P/E ratio 2025 * |
32.5
x | Employees | 8,767 |
| Yield 2024 * |
0.98% | Yield 2025 * |
1% | Free-Float | 61.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on UCB SA
More press releases
| 1 day | -0.77% | ||
| 1 week | -0.10% | ||
| Current month | +4.86% | ||
| 1 month | +5.37% | ||
| 3 months | +22.78% | ||
| 6 months | +72.77% | ||
| Current year | +78.28% |
1 week
77.60
78.95
1 month
72.6378.95
Current year
43.1778.95
1 year
34.8578.95
3 years
32.8278.95
5 years
32.4578.95
10 years
29.2078.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/11/01 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 01/20/01 |
| Chief Tech/Sci/R&D Officer | 63 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 28/16/28 | |
Dame Davies
BRD | Director/Board Member | 73 | 01/14/01 |
| Chief Executive Officer | 65 | 01/11/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 77.73 | -0.77% | 9 101 |
| 15/24/15 | 78.33 | -0.19% | 7,299 |
| 12/24/12 | 78.48 | +0.08% | 5,829 |
| 11/24/11 | 78.42 | -0.39% | 14,418 |
| 10/24/10 | 78.73 | +1.19% | 2,534 |
Delayed Quote OTC Markets, July 16, 2024 at 11:25 pm IST
More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
143.8
EUR
Average target price
140.3
EUR
Spread / Average Target
-2.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.40% | 10TCr | |
| +8.42% | 4.22TCr | |
| -13.29% | 3.23TCr | |
| -11.53% | 1.61TCr | |
| +1.94% | 1.44TCr | |
| -6.77% | 1.2TCr | |
| +177.16% | 1.07TCr | |
| +4.12% | 889.02Cr | |
| -56.13% | 882.67Cr |
- Stock Market
- Equities
- UCB Stock
- UCBJY Stock
